{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:28:10Z","timestamp":1792290490845,"version":"4.4.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,23]]},"DOI":"10.7759\/cureus.8782","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T15:01:55Z","timestamp":1592924515000},"source":"Crossref","is-referenced-by-count":19,"title":["Parkinsonism: A Rare Adverse Effect of Valproic Acid"],"prefix":"10.7759","author":[{"given":"Abilash","family":"Muralidharan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawaria","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipanjan","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Rub","family":"Hakim Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal Haider","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Quotefa. https.\/\/quotefancy.com\/quote\/1328591\/Helen-Mirren-Parkinson-s-is-a-slow-but-inevitable-process-It-s-hard-living-with-...."},{"key":"ref2","unstructured":"Parkinson's Foundation\/Understanding Parkinsons\/Statistics. (2016). Accessed. April 2020: https:\/\/www.parkinson.org\/Understanding-Parkinsons\/Statistics#:~:text=Approximately%2060%2C000%20Americans%20are%20di...."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/febs.12335","article-title":"The hallmarks of parkinson's disease","volume":"280","author":"Antony PM","year":"2013","unstructured":"Antony PM, Diederich NJ, Kr\u00fcger R, et al.. The hallmarks of parkinson's disease. FEBS J. 2013, 280:5981-5993. 10.1111\/febs.12335","journal-title":"FEBS J"},{"key":"ref4","doi-asserted-by":"crossref","DOI":"10.1038\/ng.487","article-title":"Genome\u2010wide association study reveals genetic risk underlying Parkinson's disease","volume":"41","author":"Sim\u00f3n-S\u00e1nchez J","year":"2009","unstructured":"Sim\u00f3n-S\u00e1nchez J, Schulte C, Bras JM, et al.. Genome\u2010wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet. 2009, 41:1308-1312.","journal-title":"Nat Genet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(06)70578-6","article-title":"Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data","volume":"5","author":"Fung HC","year":"2006","unstructured":"Fung HC, Scholz S, Matarin M, et al.. Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol. 2006, 5:911-916. 10.1016\/S1474-4422(06)70578-6","journal-title":"Lancet Neurol"},{"key":"ref6","article-title":"Neurodegeneration and cognition in Parkinson's disease: a review","volume":"19","author":"Ding W","year":"2015","unstructured":"Ding W, Ding LJ, Li FF, et al.. Neurodegeneration and cognition in Parkinson's disease: a review. Eur Rev Med Pharmacol Sci. 2015, 19:2275-2281.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2015.09.034","article-title":"Cognitive impairment in Parkinson's disease and dementia with Lewy bodies","volume":"22","author":"Aarsland D","year":"2016","unstructured":"Aarsland D. Cognitive impairment in Parkinson's disease and dementia with Lewy bodies. Parkinsonism Relat Disord. 2016, 22:144-148. 10.1016\/j.parkreldis.2015.09.034","journal-title":"Parkinsonism Relat Disord"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2015.09.004","article-title":"Non-motor symptoms in Parkinson's disease","volume":"22","author":"Pfeiffer RF","year":"2016","unstructured":"Pfeiffer RF. Non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord. 2016, 22:119. 10.1016\/j.parkreldis.2015.09.004","journal-title":"Parkinsonism Relat Disord"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-150686","article-title":"Oculo-visual dysfunction in Parkinson's disease","volume":"5","author":"Armstrong RA","year":"2015","unstructured":"Armstrong RA. Oculo-visual dysfunction in Parkinson's disease. J Parkinsons Dis. 2015, 5:715-726. 10.3233\/JPD-150686","journal-title":"J Parkinsons Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/bs.irn.2017.04.007","article-title":"Visual dysfunction in Parkinson's disease","volume":"134","author":"Armstrong RA","year":"2017","unstructured":"Armstrong RA. Visual dysfunction in Parkinson's disease. Inter Rev Neurobiol. 2017, 134:921-946. 10.1016\/bs.irn.2017.04.007","journal-title":"Inter Rev Neurobiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.151179","article-title":"An update on the diagnosis and treatment of Parkinson disease","volume":"188","author":"Rizek P","year":"2016","unstructured":"Rizek P, Kumar N, Jog, et al.. An update on the diagnosis and treatment of Parkinson disease. CMAJ. 2016, 188:1157-1165. 10.1503\/cmaj.151179","journal-title":"CMAJ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for parkinson's disease","volume":"30","author":"Postuma RB","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, et al.. MDS clinical diagnostic criteria for parkinson's disease. Mov Disord. 2015, 30:1591-1601. 10.1002\/mds.26424","journal-title":"Mov Disord"},{"key":"ref13","article-title":"Clinical effectiveness and cost-effectiveness of physiotherapy and occupational therapy versus no therapy in mild to moderate Parkinson's disease: a large pragmatic randomized controlled trial (PD REHAB). Southampton (UK): NIHR Journals Library","author":"Clarke CE","year":"2016","unstructured":"Clarke CE, Patel S, Ives N, et al.. Clinical effectiveness and cost-effectiveness of physiotherapy and occupational therapy versus no therapy in mild to moderate Parkinson's disease: a large pragmatic randomized controlled trial (PD REHAB). Southampton (UK): NIHR Journals Library. Appendix 1, UK Parkinson\u2019s Disease Society Brain Bank Diagnostic Criteria. 2016."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006560","article-title":"Life expectancy in Parkinson disease","volume":"91","author":"Golbe LI","year":"2018","unstructured":"Golbe LI, Leyton CE. Life expectancy in Parkinson disease. Neurology. 2018, 91:991-992. 10.1212\/WNL.0000000000006560","journal-title":"Neurology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-011613-135937","article-title":"Environmental toxins and Parkinson's disease","volume":"54","author":"Goldman SM","year":"2014","unstructured":"Goldman SM. Environmental toxins and Parkinson's disease. Annu Rev Pharmacol Toxicol. 2014, 54:141-164. 10.1146\/annurev-pharmtox-011613-135937","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2013.787065","article-title":"Drug induced Parkinsonism","volume":"12","author":"L\u00f3pez-Send\u00f3n J","year":"2013","unstructured":"L\u00f3pez-Send\u00f3n J, Mena MA, de Y\u00e9benes JG. Drug induced Parkinsonism. Expert Opin Drug Saf. 2013, 12:487-496. 10.1517\/14740338.2013.787065","journal-title":"Expert Opin Drug Saf"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-64029-1.00017-5","article-title":"Seizure classification, etiology, and management","volume":"162","author":"Shellhaas RA","year":"2019","unstructured":"Shellhaas RA. Seizure classification, etiology, and management. Handb Clin Neurol. 2019, 162:347-361. 10.1016\/B978-0-444-64029-1.00017-5","journal-title":"Handb Clin Neurol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32596-0","article-title":"Epilepsy in adults","volume":"393","author":"Thijs RD","year":"2019","unstructured":"Thijs RD, Surges R, O'Brien TJ, et al.. Epilepsy in adults. Lancet. 2019, 393:689-701. 10.1016\/S0140-6736(18)32596-0","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1684\/epd.2015.0751","article-title":"The natural history and prognosis of epilepsy","volume":"17","author":"Beghi E","year":"2015","unstructured":"Beghi E, Giussani G, Sander JW. The natural history and prognosis of epilepsy. Epileptic Disord. 2015, 17:243-253. 10.1684\/epd.2015.0751","journal-title":"Epileptic Disord"},{"key":"ref20","unstructured":"Epilepsy Statistics. (2013). Accessed. April 2020: https:\/\/www.epilepsy.com\/learn\/about-epilepsy-basics\/epilepsy-statistics."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00398-1","article-title":"The remarkable story of valproic acid","volume":"15","author":"Tomson T","year":"2016","unstructured":"Tomson T, Battino D, Perucca E. The remarkable story of valproic acid. Lancet Neurol. 2016, 15:141. 10.1016\/S1474-4422(15)00398-1","journal-title":"Lancet Neurol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e32835ea0b2","article-title":"Valproic acid pathway - pharmacokinetics and pharmacodynamics","volume":"23","author":"Ghodke-Puranik Y","year":"2013","unstructured":"Ghodke-Puranik Y, Thorn CF, Lamba JK, et al.. Valproic acid pathway - pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2013, 23:236-241. 10.1097\/FPC.0b013e32835ea0b2","journal-title":"Pharmacogenet Genomics"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2014.06.023","article-title":"A physiologically based pharmacokinetic model for valproic acid in adults and children","volume":"63","author":"Ogungbenro K","year":"2014","unstructured":"Ogungbenro K, Aarons L. A physiologically based pharmacokinetic model for valproic acid in adults and children. Eur J Pharm Sci. 2014, 63:45-52. 10.1016\/j.ejps.2014.06.023","journal-title":"Eur J Pharm Sci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/0304-4165(90)90079-c","article-title":"The enzymatic basis for the metabolism and inhibitory effects of valproic acid: dehydrogenation of valproyl-CoA by 2-methyl-branched-chain acyl-CoA dehydrogenase","volume":"1034","author":"Ito M","year":"1990","unstructured":"Ito M, Ikeda Y, Arnez JG, et al.. The enzymatic basis for the metabolism and inhibitory effects of valproic acid: dehydrogenation of valproyl-CoA by 2-methyl-branched-chain acyl-CoA dehydrogenase. Biochim Biophys Acta. 1990, 1034:213-218. 10.1016\/0304-4165(90)90079-c","journal-title":"Biochim Biophys Acta"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M101287200","article-title":"Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen","volume":"276","author":"Phiel CJ","year":"2001","unstructured":"Phiel CJ, Zhang F, Huang EY, et al.. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem. 2001, 276:36734-36741. 10.1074\/jbc.M101287200","journal-title":"J Biol Chem"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000084","article-title":"Effects of long-term valproic acid treatment on hematological and biochemical parameters in adolescent psychiatric inpatients: a retrospective naturalistic study","volume":"30","author":"Amitai M","year":"2015","unstructured":"Amitai M, Sachs E, Zivony A, et al.. Effects of long-term valproic acid treatment on hematological and biochemical parameters in adolescent psychiatric inpatients: a retrospective naturalistic study. Int Clin Psychopharmacol. 2015, 30:241-248. 10.1097\/YIC.0000000000000084","journal-title":"Int Clin Psychopharmacol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ntt.2013.01.004","article-title":"In utero exposure to valproic acid and autism-a current review of clinical and animal studies","volume":"36","author":"Roullet FI","year":"2013","unstructured":"Roullet FI, Lai JK, Foster JA. In utero exposure to valproic acid and autism-a current review of clinical and animal studies. Neurotoxicol Teratol. 2013, 36:47-56. 10.1016\/j.ntt.2013.01.004","journal-title":"Neurotoxicol Teratol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/479364","article-title":"Molecular and therapeutic potential and toxicity of valproic acid","volume":"2010","author":"S\u00e9bastien C","year":"2010","unstructured":"S\u00e9bastien C, Franck M, Mario D, et al.. Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol. 2010, 2010:479364.. 10.1155\/2010\/479364","journal-title":"J Biomed Biotechnol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629010-00001","article-title":"Valproic acid in epilepsy-pregnancy related issues","volume":"29","author":"Genton P","year":"2006","unstructured":"Genton P, Semah F, Trinka E. Valproic acid in epilepsy-pregnancy related issues. Drug Saf. 2006, 29:1-21. 10.2165\/00002018-200629010-00001","journal-title":"Drug Saf"},{"key":"ref30","article-title":"Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy","volume":"47","author":"Davis R","year":"1994","unstructured":"Davis R, Peters DH, McTavish D. Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs. 1994, 47:332-372.","journal-title":"Drugs"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.psym.2015.09.008","article-title":"Valproic acid for treatment of hyperactive or mixed delirium - rationale and literature review","volume":"56","author":"Sher Y","year":"2015","unstructured":"Sher Y, Miller CAC, Ament A, et al.. Valproic acid for treatment of hyperactive or mixed delirium - rationale and literature review. Psychosomatics. 2015, 56:615-625. 10.1016\/j.psym.2015.09.008","journal-title":"Psychosomatics"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3233\/RNN-160704","article-title":"Use of melatonin versus valproic acid in prophylaxis of migraine patients: a double-blind, randomized clinical trial","volume":"35","author":"Ebrahimi M","year":"2017","unstructured":"Ebrahimi M, Sharafkhah M, Abdolrazaghnejad A, et.al.. Use of melatonin versus valproic acid in prophylaxis of migraine patients: a double-blind, randomized clinical trial. Restor Neurol Neurosci. 2017, 35:385-393. 10.3233\/RNN-160704","journal-title":"Restor Neurol Neurosci"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2018.07.057","article-title":"Valproic acid as an adjunctive therapeutic agent for the treatment of breast cancer","volume":"835","author":"Heers H","year":"2018","unstructured":"Heers H, Stanislaw J, Harrelson J, et al.. Valproic acid as an adjunctive therapeutic agent for the treatment of breast cancer. Eur J Pharmacol. 2018, 835:61-74. 10.1016\/j.ejphar.2018.07.057","journal-title":"Eur J Pharmacol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2013.787065","article-title":"Drug-induced Parkinsonism","volume":"12","author":"L\u00f3pez SJ","year":"2013","unstructured":"L\u00f3pez SJ, Mena MA, de Y\u00e9benes JG. Drug-induced Parkinsonism. Expert Opin Drug Saf. 2013, 12:487-496. 10.1517\/14740338.2013.787065","journal-title":"Expert Opin Drug Saf"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26839","article-title":"Incidence and time trends of drug-induced Parkinsonism - a 30-year population-based study","volume":"32","author":"Savica R","year":"2017","unstructured":"Savica R, Grossardt BR, Bower JH, et al.. Incidence and time trends of drug-induced Parkinsonism - a 30-year population-based study. Mov Disord. 2017, 32:227-234. 10.1002\/mds.26839","journal-title":"Mov Disord"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-019-7664-6","article-title":"Prevalence and incidence of Parkinson's disease and drug-induced Parkinsonism in Korea","volume":"19","author":"Han S","year":"2019","unstructured":"Han S, Kim S, Kim H, et al.. Prevalence and incidence of Parkinson's disease and drug-induced Parkinsonism in Korea. BMC Public Health. 2019, 19:1328-2019. 10.1186\/s12889-019-7664-6","journal-title":"BMC Public Health"},{"key":"ref37","article-title":"Tardive dyskinesia, mild drug-induced dyskinesia, and drug-induced parkinsonism: risk factors and topographic distribution","volume":"99","author":"Akbostanci MC","year":"1999","unstructured":"Akbostanci MC, Atba\u015fo\u011flu EC, Balaban H. Tardive dyskinesia, mild drug-induced dyskinesia, and drug-induced parkinsonism: risk factors and topographic distribution. Acta Neurol Belg. 1999, 99:176-181.","journal-title":"Acta Neurol Belg"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.2008.073312","article-title":"Drug-induced Parkinsonism - a common cause of Parkinsonism in older people","volume":"85","author":"Thanvi B","year":"2009","unstructured":"Thanvi B, Treadwell S. Drug-induced Parkinsonism - a common cause of Parkinsonism in older people. Postgrad Med J. 2009, 85:322-326. 10.1136\/pgmj.2008.073312","journal-title":"Postgrad Med J"},{"key":"ref39","article-title":"Risk factors for drug-induced parkinsonism in tardive dyskinesia patients","volume":"49","author":"Hansen TE","year":"1988","unstructured":"Hansen TE, Brown WL, Weigel RM, et al.. Risk factors for drug-induced parkinsonism in tardive dyskinesia patients. J Clin Psychiatry. 1988, 49:139-141.","journal-title":"J Clin Psychiatry"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2014.05.011","article-title":"Differentiating drug-induced parkinsonism from Parkinson's disease: an update on non-motor symptoms and investigations","volume":"20","author":"Brigo F","year":"2014","unstructured":"Brigo F, Erro R, Marangi A, et al.. Differentiating drug-induced parkinsonism from Parkinson's disease: an update on non-motor symptoms and investigations. Parkinsonism Relat Disord. 2014, 20:808-814. 10.1016\/j.parkreldis.2014.05.011","journal-title":"Parkinsonism Relat Disord"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2012.8.1.15","article-title":"Drug induced Parkinsonism","volume":"8","author":"Shin HW","year":"2012","unstructured":"Shin HW, Chung SJ. Drug induced Parkinsonism. J Clin Neurol. 2012, 8:15-21. 10.3988\/jcn.2012.8.1.15","journal-title":"J Clin Neurol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.2147\/JPRLS.S99197","article-title":"Drug induced Parkinsonism - diagnosis and management","volume":"8","author":"Blanchet P","year":"2016","unstructured":"Blanchet P, Kivenko V. Drug induced Parkinsonism - diagnosis and management. Res Rev Parkinsonism. 2016, 8:83-91. 10.2147\/JPRLS.S99197","journal-title":"Res Rev Parkinsonism"},{"key":"ref43","article-title":"Drug-induced Parkinsonian syndromes: a 10-year experience at a regional center of pharmaco-vigilance","volume":"150","author":"Llau ME","year":"1994","unstructured":"Llau ME, Nguyen L, Senard JM, et al.. Drug-induced Parkinsonian syndromes: a 10-year experience at a regional center of pharmaco-vigilance. Rev Neurol (Paris). 1994, 150:757-762.","journal-title":"Rev Neurol (Paris)"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2014.11.007","article-title":"Dopamine transporter imaging as a diagnostic tool for Parkinsonism and related disorders in clinical practice","volume":"21","author":"Ba F","year":"2015","unstructured":"Ba F, Martin WR. Dopamine transporter imaging as a diagnostic tool for Parkinsonism and related disorders in clinical practice. Parkinsonism Relat Disord. 2015, 21:87-94. 10.1016\/j.parkreldis.2014.11.007","journal-title":"Parkinsonism Relat Disord"},{"key":"ref45","article-title":"New diagnostic criteria for Parkinsons disease : MDS-PD criteria","volume":"70","author":"Watanabe H","year":"2018","unstructured":"Watanabe H, Hara K, Ito M, et al.. New diagnostic criteria for Parkinsons disease : MDS-PD criteria. Brain Nerve. 2018, 70:139-146.","journal-title":"Brain Nerve"},{"key":"ref46","article-title":"Reversible valproic acid-induced Parkinsonism and cognitive impairment in an elderly patient with bipolar disorder I","volume":"27","author":"Hassamal S","year":"2016","unstructured":"Hassamal S, Waller S, Reese K, et al.. Reversible valproic acid-induced Parkinsonism and cognitive impairment in an elderly patient with bipolar disorder I. Turk Psikiyatri Derg. 2016, 27:213-217.","journal-title":"Turk Psikiyatri Derg"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2013.03.016","article-title":"Valproic acid-induced Parkinsonism: levodopa responsiveness with dyskinesia","volume":"19","author":"Silver M","year":"2013","unstructured":"Silver M, Factor SA. Valproic acid-induced Parkinsonism: levodopa responsiveness with dyskinesia. Parkinsonism Relat Disord. 2013, 19:758-760. 10.1016\/j.parkreldis.2013.03.016","journal-title":"Parkinsonism Relat Disord"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjopharm.2011.09.002","article-title":"Valproic acid-induced parkinsonism in the elderly- a comprehensive review of the literature","volume":"9","author":"Mahmoud F","year":"2011","unstructured":"Mahmoud F, Tampi RR. Valproic acid-induced parkinsonism in the elderly- a comprehensive review of the literature. Am J Geriatr Pharmacother. 2011, 9:405-412. 10.1016\/j.amjopharm.2011.09.002","journal-title":"Am J Geriatr Pharmacother"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-931471","article-title":"Parkinsonism and\/or cognitive impairment with valproic acid therapy - a report of ten cases","volume":"39","author":"Masmoudi K","year":"2006","unstructured":"Masmoudi K, Gras CV, Masson H, et al.. Parkinsonism and\/or cognitive impairment with valproic acid therapy - a report of ten cases. Pharmacopsychiatry. 2006, 39:9-12. 10.1055\/s-2006-931471","journal-title":"Pharmacopsychiatry"},{"key":"ref50","article-title":"Valproate induced Parkinsonism","volume":"50","author":"Park M","year":"1998","unstructured":"Park M, Tazawa T. Valproate induced Parkinsonism.  No To Shinkei. 1998, 50:81-84.","journal-title":"No To Shinkei"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/33023-parkinsonism-a-rare-adverse-effect-of-valproic-acid","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:26:37Z","timestamp":1707506797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/33023-parkinsonism-a-rare-adverse-effect-of-valproic-acid"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,23]]},"references-count":50,"URL":"https:\/\/doi.org\/10.7759\/cureus.8782","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,23]]}}}